Ocular Therapeutix (OCUL) Interest Expenses (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Interest Expenses of $2.8 million for Q2 2026, down 7.43% year-over-year from $3.0 million in Q2 2025, and up 0.54% on a QoQ basis from $2.8 million in Q1 2026.
Ocular Therapeutix (OCUL) Interest Expenses (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Interest Expenses for 14 years, with the latest figure at $2.8 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $2.8 million, down 7.43% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.4 million (down 7.52% YoY), and the FY2025 annual result was $292.4 million, up 29.83% from the prior year.
- Interest Expenses rose to $2.8 million in Q2 2026, from $2.8 million in the prior quarter.
- Over five years, Interest Expenses peaked at $13.0 million in Q1 2024 and troughed at -$1.7 million in Q4 2023.
- A 5-year average of $2.8 million and a median of $2.8 million in 2025 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2022, when Interest Expenses tumbled 218.61%; it then soared 633.43% in 2024.
- A 5-year view of Interest Expenses shows it stood at -$580000.0 in 2022, then tumbled by 197.07% to -$1.7 million in 2023, then jumped by 280.27% to $3.1 million in 2024, then slipped by 8.82% to $2.8 million in 2025, then retreated by 1.41% to $2.8 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $2.8 million in Q2 2026, $2.8 million in Q1 2026, and $2.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.79 Mn |
| Jun 30, 2026 | 2.79 Mn |
| Mar 31, 2026 | 2.78 Mn |
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 26,000.00 |
| Dec 31, 2025 | 26,000.00 |
| Sep 30, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.02 Mn |
| Jun 30, 2025 | 3.02 Mn |
| Mar 31, 2025 | 2.98 Mn |
| Mar 31, 2025 | 2.98 Mn |
| Dec 31, 2024 | 11.06 Mn |
| Dec 31, 2024 | 11.06 Mn |
| Sep 30, 2024 | 3.22 Mn |
| Sep 30, 2024 | 3.22 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Mar 31, 2024 | 12.97 Mn |
| Mar 31, 2024 | 12.97 Mn |